The mechanism of cancer immunotherapy is the use of immune system to treat cancer. And the Immune system is the built-in host defense mechanism which can fight against infectious agents as well as cancer. Since in 1940s, the first protective immunity against cancer was convincingly demonstrated with syn-geneic animal models, last century’s dream was to effectively prevent and cure cancers by immunological means. Individualized cancer therapy is a central goal of cancer biologists. In past years, this dream has slowly but surely become a reality. Immunotherapy is a rational means to this end—because the immune system can recognize a virtually limitless number of antigens secondary to the biology of genetic recombination in B and T lymphocytes. The Understanding of the interaction between cancer and immune system provides insights into mechanisms that can be exploited to disinhibit anti-tumor immune responses. This book covers the first-hand data in the field of cancer immunotherapy re-search, introducing the research status, the newest development, problems and outlook of cancer immunotherapy. The book is suitable for clinical practitioners and scientists; medical and medicinal students; medicinal researchers and those with an interest in cancer immunotherapy. Suggestions and opinions from read-ers are welcome.
Components of the Book:
- FRONT MATTER
- Chapter 1
Primer on Tumor Immunology and Cancer Immunotherapy
- Chapter 2
Cancer Immunotherapy: Are We There Yet?
- Chapter 3
Highlights and Summary of the 28th Annual Meeting of the Society for Immunotherapy of Cancer
- Chapter 4
Towards Efficient Cancer Immunotherapy: Advances in Developing Artificial Antigen-Presenting Cells
- Chapter 5
Chimeric Antigen Receptor for Adoptive Immunotherapy of Cancer: Latest Research and Future Prospects
- Chapter 6
Chimeric Antigen Receptor-Engineered T Cells for Cancer Immunotherapy: Progress and Challenges Prospects
- Chapter 7
The Development of Immunomodulatory Monoclonal Antibodies as a New Therapeutic Modality for Cancer: The Bristol-Myers Squibb Experience
- Chapter 8
A2aR Antagonists: Next Generation Checkpoint Blockade for Cancer Immunotherapy
- Chapter 9
New Perspective on Targeting the Tumor Suppressor p53 Pathway in the Tumor Microenvironment to Enhance the Efficacy of Immunotherapy
- Chapter 10
Bridging Infectious Disease Vaccines with Cancer Immunotherapy: A Role for Targeted RNA based Immunotherapeutics
- Chapter 11
Enhancing the Discovery and Development of Immunotherapies for Cancer Using Quantitative and Systems Pharmacology: Interleukin-12 as a Case Study
- Chapter 12
Novel Technologies and Emerging Biomarkers for Personalized Cancer Immunotherapy
- Chapter 13
Current status of Granulocyte-Macrophage Colony-Stimulating Factor in the Immunotherapy of Melanoma
- Chapter 14
Advances in Immunotherapy for Melanoma
- Chapter 15
Immunotherapy in Endometrial Cancer—An Evolving Therapeutic Paradigm
Readership:
Students, academics, teachers and other people attending or interested in Cancer Immunotherapy.
Bernard A Fox
Ph.D., Earle A. Chiles Research Institute, Providence Cancer Center, 4805 NE Glisan Street, Portland, OR 97213, USA.
Carl G. Figdor
Head of Department, Department of Tumor Immunology,
Radboud University Medical Centre and Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Craig Slingluff
Professor; Vice-Chair for Research, University of Virginia, P.O. Box 800709, Charlottesville, VA 22908, USA.
David Klinke
Ph.D., Department of Chemical Engineering and Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 25606, USA.
Luis Sanchez-Perez
Assistant Professor, Division of Neurosurgery, Department of Surgery, Duke Brain Tumor Immunotherapy Program, Duke University Medical Center, Durham, NC, USA.
Paolo Antonio Ascierto
Director, Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione “G. Pascale”, Naples, Italy.
and more...